A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720)

This study has been terminated.
(The study was prematurely terminated for strategic reasons, not for a safety concern.)
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT00617890
First received: January 17, 2008
Last updated: July 19, 2016
Last verified: July 2016

January 17, 2008
July 19, 2016
February 2008
August 2011   (final data collection date for primary outcome measure)
  • Number of Participants Achieving a Complete Response or Partial Response (Group 3 Only) [ Time Frame: Up to 1 year following the start of study therapy ] [ Designated as safety issue: No ]
    This is a measure of the number of participants with a complete response (CR) or partial response (PR) to therapy, confirmed by central review. Response was based on Response Evaluation Criteria in Solid Tumors (RECIST) and World Health Organization (WHO) criteria.
  • Number of Participants With >= 25% Change in Tumor Proliferation After Exposure to Robatumumab (Group 1 Only) [ Time Frame: Approximately 14 days ] [ Designated as safety issue: No ]
    Tumor proliferation was measured using Ki-67 levels. Ki-67 is nuclear protein associated with cellular proliferation.
  • Number of Participants Achieving a Complete Response, a Partial Response, or Stable Disease (Group 2 Only) [ Time Frame: Up to 1 year following the start of study therapy ] [ Designated as safety issue: No ]
    Responses to treatment (complete response, partial response, or stable disease) confirmed by central review for Participants in Group 2. Response was based on Response Evaluation Criteria in Solid Tumors (RECIST) and World Health Organization (WHO) criteria.
  • For subjects with resectable osteosarcoma: change in tumor proliferation rate. [ Time Frame: Approximately 14 days ] [ Designated as safety issue: No ]
  • For subjects with unresectable osteosarcoma or Ewing's sarcoma: tumor response rate. [ Time Frame: until disease progression ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00617890 on ClinicalTrials.gov Archive Site
  • Overall Survival [ Time Frame: From start of treatment until death or data analysis cut off (Up to 3.4 years) ] [ Designated as safety issue: No ]
    This is a measure of the number of participants known to be alive at the time of data analysis for this study.
  • Time Until Tumor Relapse (Group 1 Only) [ Time Frame: From start of treatment until relapse or data analysis cut off (Up to 3.4 years) ] [ Designated as safety issue: No ]
    This is a measure of the time from the start of the study to documented relapse of disease.
  • Area Under the Concentration-time Curve (AUC) of Serum Levels of Robatumumab (Group 1 Only) [ Time Frame: End of infusion on Day 1, and then prior to surgery, before and after the 2nd, 3rd, and 8th doses (up to 20 weeks) ] [ Designated as safety issue: No ]
  • Incidence of Anti-robatumumab Antibodies [ Time Frame: Up to 2 years ] [ Designated as safety issue: No ]
    For biological agents, it is possible for the host (participant) to develop antibodies to the agent. This outcome measure was planned to find out the number of participants who developed the antibodies after treatment with robatumumab.
  • Number of Participants Experiencing Treatment-Emergent Adverse Events [ Time Frame: Up to 2 years ] [ Designated as safety issue: Yes ]
    An adverse event is any unfavorable and unintended change in the structure, function, or chemistry of the body whether or not considered related to the study treatment. Treatment-emergent adverse events are those that occur after participants have received study treatment, or existing adverse events that occurred during screening that increase in severity after study treatment. Adverse events in the Group 1: 0.3 mg/kg arm that occurred after switching to the 10 mg/kg dose are displayed under the originally assigned treatment.
  • Time to Disease Progression (Groups 2 and 3 Only) [ Time Frame: From the start of treatment until disease progression or data analysis cut off (Up to 3.4 years) ] [ Designated as safety issue: No ]
    This is a measure of the time from the start of the study to the time of documented disease progression.
  • Overall Survival (Groups 2 and 3 Only) [ Time Frame: From start of treatment until death or data analysis cut off (Up to 3.4 years) ] [ Designated as safety issue: No ]
    This is a measure of the time of survival from first dose to documentation of death
  • Duration of Response (Groups 2 and 3 Only) [ Time Frame: From time of documented response until disease progression or data analysis cut off (Up to 3.4 years) ] [ Designated as safety issue: No ]
    This is a measure of the amount of time in which the tumor responded to therapy.
  • For subjects with resectable osteosarcoma: Time to progression. [ Time Frame: Until disease progression or one year of dosing. ] [ Designated as safety issue: No ]
  • Pharmacokinetic data [ Time Frame: Evaluation up to eighth dose. ] [ Designated as safety issue: No ]
  • Pharmacodynamic parameters will be assessed. [ Time Frame: Throughout the study ] [ Designated as safety issue: No ]
  • Safety [ Time Frame: Throughout the study ] [ Designated as safety issue: Yes ]
Not Provided
Not Provided
 
A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720)
A Study to Determine the Activity of SCH 717454 in Subjects With Osteosarcoma or Ewing's Sarcoma That Has Relapsed After Standard Systemic Therapy

Participants with relapsed osteosarcoma that can be treated with surgery will be randomized to robatumumab administered intravenously (IV) at one of two dose levels. These participants will first receive robatumumab, have surgery performed, and continue to receive treatment every two weeks until a year of dosing, or until disease progression.

Participants with unresectable osteosarcoma or Ewing Sarcoma will receive robatumumab IV once every two weeks until disease progression. Participants who achieve a complete response (CR) or partial response (PR) after tumor evaluations may undergo surgical resection. After surgery, participants are eligible to receive 10 mg/kg robatumumab until disease recurrence/progression or one year of total dosing, whichever occurs first.

Participants with resectable osteosarcoma will be randomized to one of two dose levels of robatumumab to be given intravenously. These participants will first receive robatumumab according to randomized treatment, and have surgery performed 10 to 14 days after initial dosing. Participants will be allowed to recover from surgery four to six weeks prior to additional robatumumab administration at their randomized dose level. robatumumab will then be administered on the same calendar day once every two weeks. Participants will continue to receive robatumumab until disease recurrence, or until completing a year of dosing at the same dose level assigned, whichever occurs first.

Participants with unresectable osteosarcoma or Ewing Sarcoma will be assigned treatment to robatumumab IV administered once every two weeks and will continue to receive robatumumab until disease progression. Participants who achieve a CR or PR after tumor evaluations may undergo surgical resection. After surgery, participants are eligible to receive 10 mg/kg robatumumab until disease recurrence/progression or one year of total dosing, whichever occurs first.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
  • Osteosarcoma
  • Sarcoma, Ewing's
  • Peripheral Neuroectodermal Tumor
Biological: robatumumab
Robatumumab IV every two weeks until disease progression.
Other Names:
  • SCH 717454
  • SCH 717454 (19D12)
  • MK-7454
  • Experimental: Group 1: 0.3 mg/kg
    Participants received robatumumab 0.3 mg/kg intravenously (IV) as a single dose on Day 1, followed by surgery on Day 10 to 14, and four weeks later, resumption of robatumumab 0.3 mg/kg on the same calendar day (± 3 days) once every 2 weeks until disease recurrence or up to 1 year of dosing. This group comprised participants with resectable osteosarcoma that relapsed within 6 months of prior definitive treatment (eg surgical metastasectomy) and having at least one prior chemotherapy regimen containing a platinum agent and doxorubicin.
    Intervention: Biological: robatumumab
  • Experimental: Group 1: 10 mg/kg
    Participants who received robatumumab 10 mg/kg IV as a single dose on Day 1, followed by surgery on Day 10 to 14, and four weeks later, resumption of robatumumab 10 mg/kg on the same calendar day (± 3 days) once every 2 weeks until disease recurrence or up to 1 year of dosing. This group comprised participants with resectable osteosarcoma that relapsed within 6 months of prior definitive treatment (eg surgical metastasectomy) and having at least one prior chemotherapy regimen containing a platinum agent and doxorubicin.
    Intervention: Biological: robatumumab
  • Experimental: Group 2: 10 mg/kg
    Participants received robatumumab 10 mg/kg IV biweekly until disease recurrence or up to 1 year of dosing. This group comprised participants with relapsed and unresectable osteosarcoma refractory to prior chemotherapy with a platinum- and doxorubicin-containing regimen.
    Intervention: Biological: robatumumab
  • Experimental: Group 3: 10 mg/kg
    Participants received robatumumab 10 mg/kg IV biweekly until disease recurrence or up to 1 year of dosing. This group comprised participants with Ewing sarcoma refractory to prior treatment with at least 3 of the following agents: ifosfamide, etoposide, cyclophosphamide, doxorubicin, or vincristine.
    Intervention: Biological: robatumumab
Asmane I, Watkin E, Alberti L, Duc A, Marec-Berard P, Ray-Coquard I, Cassier P, Decouvelaere AV, Ranchère D, Kurtz JE, Bergerat JP, Blay JY. Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas. Eur J Cancer. 2012 Nov;48(16):3027-35. doi: 10.1016/j.ejca.2012.05.009. Epub 2012 Jun 7.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
219
August 2013
August 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • A participant must be 11 years of age or older and may be of any race, and gender; participants between 4 and 10 years of age, inclusive, may be considered on a site-by-site basis.
  • A participant must have a diagnosis of histologically confirmed osteosarcoma or Ewing sarcoma;
  • A participant with either:

    • relapsed and resectable osteosarcoma
    • relapsed and unresectable osteosarcoma that is refractory to standard therapy, ie. has relapsed after prior systemic treatment with active chemotherapy agents
    • Ewing sarcoma that is refractory to standard systemic therapies
  • A participant >16 years of age must have an Eastern Cooperative Oncology Group (ECOG) performance status of <=2; a participant <=16 years of age must have a Karnofsky performance status between 50% and 100% or a Lansky play scale between 50% and 100%
  • A participant must have adequate organ function.

Exclusion Criteria:

  • A participant with a history of another malignancy (with the exception of non-melanoma skin cancer or carcinoma in situ of the cervix treated with curative intent at least 2 years prior to start of treatment, or other adequately treated malignancy for which the subject has been disease free for >=5 years)
  • A participant who has known treated or untreated leptomeningeal metastasis, or a metastatic central nervous system lesion
  • A participant with a history of uncontrolled diabetes mellitus
  • A participant with a recent myocardial infarction (within the past year); or a participant who at the time of Screening presents with unstable or uncontrolled angina, New York Heart Association (NYHA) Class III or IV congestive heart failure, uncontrolled hypertension, clinically significant cardiac dysrhythmia or clinically significant electrocardiogram (ECG) abnormality
  • A participant with an active infection
  • A participant with clinically significant hepatitis at Screening, or a participant who is hepatitis C antibody positive, hepatitis B surface antigen positive, or human immunodeficiency virus (HIV) seropositive
  • A participant who has been treated with an anti-insulin-like growth factor receptor 1 (anti-IGF-1R)- targeted drug or antibody
  • A participant with known hypersensitivity to other antibodies, or any accompanying excipients associated with these medications.
Both
4 Years and older   (Child, Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
Argentina,   Australia,   Brazil,   Canada,   Chile,   France,   Germany,   Guatemala,   Hungary,   Italy,   Korea, Republic of,   Mexico,   Netherlands,   New Zealand,   Norway,   Peru,   Portugal,   Spain,   Sweden,   Turkey,   United Kingdom,   United States
 
NCT00617890
P04720
No
Not Provided
Not Provided
Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp.
Not Provided
Study Director: Medical Director Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp.
July 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP